Search the literature, browse cardiology by subspecialty, and follow where the evidence and consensus are moving.
Start typing to jump to a topic, or press Enter to search the literature.
4 studies (4,508 patients) provide low-certainty evidence against benefit of tavr for All-Cause Mortality in Aortic Valve Stenosis.
High recent attention via web coverage.
2 studies (3,826 patients) provide low-certainty evidence for benefit of transcatheter tricuspid valve intervention (ttvi) for All-Cause Mortality in Tricuspid Valve Insufficiency.
2 studies (1,483 patients) provide low-certainty evidence for benefit of inspiratory muscle training (imt) for Peak Oxygen Consumption in Heart Failure, Diastolic.
2 studies (51,004 patients) provide low-certainty evidence for benefit of clopidogrel for Stroke Hospitalization in Coronary Artery Disease.
2 studies (826 patients) provide low-certainty evidence against benefit of hydroxychloroquine for QT Prolongation in COVID-19 Virus Disease.
2 studies (5,420 patients) provide insufficient evidence with mixed findings regarding fibrinolytic for Major Bleeding in ST segment elevation myocardial infarction.
Insufficient evidence (1 studies, 576853 patients) to determine the effect of 1 kg/m2 increment of bmi (genetic instrument) on All-Cause Mortality in Heart failure.
Evidence is new dissent on subcutaneous implantable cardioverter defibrillator (s-icd).
2 studies (5,494 patients) provide insufficient evidence with mixed findings regarding subcutaneous implantable cardioverter defibrillator (s-icd) for Inappropriate ICD Shocks in Wolff-Parkinson-White Syndrome.
Insufficient evidence (1 studies, 21346 patients) to determine the effect of concomitant obstructive sleep apnea (osa) on All-Cause Mortality in Cardiomyopathy, Hypertrophic.
4 studies (140,763 patients) provide low-certainty evidence for benefit of antiplatelet for All-Cause Mortality in Percutaneous Coronary Intervention.
Insufficient evidence (1 studies, 1068723 patients) to determine the effect of new-urban in situ residents on Cardiovascular Mortality in Cardiovascular Diseases.
Does dapagliflozin vs placebo affect OUT:cv-death-or-worsening-hf in Heart Failure with Reduced Ejection Fraction?
1 studies (4,744 patients, 1 RCTs) provide moderate-certainty evidence for benefit of dapagliflozin for Composite of worsening HF or cardiovascular death in Heart Failure with Reduced Ejection Fraction.
Does dabigatran vs warfarin improve outcomes in HEART-VALVE, MECHANICAL?
25 studies (732,515 patients) provide low-certainty evidence for benefit of dabigatran for Ventricular Arrhythmia in HEART-VALVE, MECHANICAL.
Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?
25 studies (460,637 patients) provide low-certainty evidence for benefit of immune checkpoint inhibitors for Cardiac Index in cancer therapy-related cardiovascular toxicity.
Does rivaroxaban vs apixaban improve outcomes in Venous Thromboembolism?
5 studies (48,024 patients) provide low-certainty evidence for benefit of rivaroxaban for Cardiac Output in Venous Thromboembolism.
Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in Acute Coronary Syndrome?
3 studies (41,464 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in Acute Coronary Syndrome.
Does inspiratory muscle training (imt) vs placebo improve Peak Oxygen Consumption in Heart Failure, Diastolic?
2 studies (1,483 patients) provide low-certainty evidence for benefit of inspiratory muscle training (imt) for Peak Oxygen Consumption in Heart Failure, Diastolic.
Does amiodarone vs placebo improve outcomes in Atrial Fibrillation?
10 studies (49,075 patients) provide low-certainty evidence against benefit of amiodarone for Myocardial Infarction Hospitalization in Atrial Fibrillation.
Does apixaban vs enoxaparin improve outcomes in Venous Thromboembolism?
6 studies (6,044 patients) provide low-certainty evidence against benefit of apixaban for Cardiac Output in Venous Thromboembolism.
Does asparaginase vs placebo improve outcomes in L2 Acute Lymphoblastic Leukemia?
4 studies (221 patients) provide low-certainty evidence against benefit of asparaginase for Myocardial Infarction Hospitalization in L2 Acute Lymphoblastic Leukemia.
Does phenylephrine vs placebo improve Systolic Blood Pressure?
2 studies (45 patients) provide low-certainty evidence against benefit of phenylephrine for Systolic Blood Pressure in this population.
Does dipyridamole vs placebo improve Left Ventricular Ejection Fraction in Aortic Valve Stenosis?
2 studies (30 patients) provide low-certainty evidence against benefit of dipyridamole for Left Ventricular Ejection Fraction in Aortic Valve Stenosis.
Create a free account to filter by intervention × outcome, follow individual questions, and get notified as new RCTs change the picture.